Concordia Healthcare Corp. (NASDAQ:CXRX)‘s stock had its “outperform” rating reaffirmed by stock analysts at RBC Capital Markets in a report issued on Monday. They presently have a $18.00 price target on the stock, down from their prior price target of $32.00. RBC Capital Markets’ target price would indicate a potential upside of 251.56% from the company’s current price.

CXRX has been the topic of several other reports. Zacks Investment Research upgraded Concordia Healthcare Corp. from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Wednesday, July 13th. Goldman Sachs Group Inc. started coverage on Concordia Healthcare Corp. in a research note on Monday, June 6th. They set a “neutral” rating and a $32.00 target price on the stock. TD Securities reiterated a “buy” rating and set a $37.00 price target (down previously from $45.00) on shares of Concordia Healthcare Corp. in a research note on Wednesday, June 29th. Canaccord Genuity set a $20.00 price target on Concordia Healthcare Corp. and gave the company a “buy” rating in a research note on Monday, August 15th. Finally, CIBC downgraded Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 price target on the stock. in a research note on Monday, August 15th. Two analysts have rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $37.79.

Concordia Healthcare Corp. (NASDAQ:CXRX) opened at 5.12 on Monday. The stock has a 50 day moving average price of $9.89 and a 200 day moving average price of $21.62. Concordia Healthcare Corp. has a 1-year low of $4.80 and a 1-year high of $69.60. The company’s market cap is $261.21 million.

Concordia Healthcare Corp. (NASDAQ:CXRX) last announced its earnings results on Friday, August 12th. The company reported $1.38 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.38. Concordia Healthcare Corp. had a positive return on equity of 25.18% and a negative net margin of 81.80%. The firm had revenue of $231.70 million for the quarter, compared to the consensus estimate of $229.76 million. The firm’s revenue for the quarter was up 208.1% on a year-over-year basis. On average, equities research analysts anticipate that Concordia Healthcare Corp. will post $5.21 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in CXRX. Taylor Asset Management Inc. boosted its position in Concordia Healthcare Corp. by 244.0% in the second quarter. Taylor Asset Management Inc. now owns 923,400 shares of the company’s stock worth $19,895,000 after buying an additional 655,000 shares during the last quarter. Nomura Holdings Inc. boosted its position in Concordia Healthcare Corp. by 1,183.4% in the second quarter. Nomura Holdings Inc. now owns 552,150 shares of the company’s stock worth $11,939,000 after buying an additional 509,127 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in Concordia Healthcare Corp. during the second quarter worth $1,855,000. Royal Bank of Canada boosted its position in Concordia Healthcare Corp. by 18.2% in the first quarter. Royal Bank of Canada now owns 850,647 shares of the company’s stock worth $21,776,000 after buying an additional 130,705 shares during the last quarter. Finally, HRS Investment Holdings LLC boosted its position in Concordia Healthcare Corp. by 100.0% in the first quarter. HRS Investment Holdings LLC now owns 15,400 shares of the company’s stock worth $394,000 after buying an additional 7,700 shares during the last quarter. 33.93% of the stock is owned by institutional investors.

Concordia Healthcare Corp. Company Profile

5 Day Chart for NASDAQ:CXRX

Receive News & Ratings for Concordia Healthcare Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp. and related companies with MarketBeat.com's FREE daily email newsletter.